Vorasidenib
servier
['vorasidenib']
breakthrough research in led by dr. ingo mellinghoff found that #vorasidenib, an oral dual inhibitor of mutant idh1/2 enzymes, significantly improved progression-free survival in patients with grade 2 diffuse gliomas, a type of #braintumor. #asco23 
One of the world’s leading comprehensive cancer centers. To make an appointment: (833) 390-0294